FDA Approved Products

Application #TypeSponsorNotesProduct #Drug NameFormStrengthActive IngredientApproval DateMarketing StatusReference Standard
217171NDAAPELLIS PHARMS001SYFOVRESOLUTION;INTRAVITREAL15MG/0.1ML (15MG/0.1ML)PEGCETACOPLAN2023-02-17PrescriptionYes
215014NDAAPELLIS PHARMS001EMPAVELISOLUTION;SUBCUTANEOUS1080MG/20ML (54MG/ML)PEGCETACOPLAN2021-05-14PrescriptionYes